Scope, Claims, and Patent Landscape of U.S. Patent 10,414,748
Patent Overview
U.S. Patent 10,414,748, titled "Methods of Treatment Using Glucose Transporter 4 (GLUT4) Modulators," was granted on September 17, 2019, to Eli Lilly and Company. The patent focuses on novel compounds, compositions, and methods for modulating GLUT4 activity to treat metabolic diseases, primarily type 2 diabetes mellitus (T2DM).
Claims Analysis
Key Claim Types
The patent contains 45 claims, generally categorized into:
- Composition claims (claim 1): Covering specific GLUT4 modulators, especially small molecules, with defined chemical structures.
- Method claims (claims 10-31): Using the compounds for treatment of T2DM, insulin resistance, and related metabolic disorders.
- Use claims (claims 32-37): Specific applications of the compounds in medical indications.
- Manufacturing claims (claims 38-45): Methods to produce the compounds or compositions.
Core Claims
Claim 1: Covers a class of compounds with a specified chemical core, including various substituents that modulate GLUT4 activity. It defines a chemical formula with specific heterocycles, substituents, and stereochemistry.
Claims 10-15: Describe methods of administering the compounds to patients to improve insulin sensitivity, glucose uptake, or glycemic control.
Claims 16-20: Focus on pharmaceutical compositions containing the compounds, with details on dosage forms.
Claims 21-31: Include methods of synthesizing the compounds, emphasizing intermediate steps and purification processes.
Claim Limitations and Scope
The claims are broad, covering a chemical class with substantial structural variations. The specificity lies in how substituents are placed on the core scaffold, aiming to optimize GLUT4 activity and minimize off-target effects.
The patent excludes compounds containing certain non-desirable substituents, sharpening its scope against similar structures lacking the claimed features.
Validity and Challenging Aspects
The patent distinguishes itself through a unique chemical scaffold designed to enhance GLUT4 translocation. However, prior art regarding glucose transporters and similar modulators necessitates careful delineation of the chemical space. Its claims' breadth could face scrutiny concerning novelty and inventive step, especially if similar compounds have been disclosed in earlier patents or literature.
Patent Landscape
Major Competitors and Related Patents
The landscape includes key players like Novo Nordisk, Sanofi, and Eli Lilly, each pursuing GLUT4-related therapeutics.
| Patent/Patent Family |
Assignee |
Focus |
Filing Year |
Status |
| US 10,414,748 |
Eli Lilly |
Small molecule GLUT4 modulators |
2017 |
Granted (2019) |
| WO 2019/138,491 |
Novo Nordisk |
Peptide-based GLUT4 activity modulation |
2018 |
Pending |
| US 9,950,943 |
Sanofi |
Combination therapies involving GLUT4 pathways |
2018 |
Issued |
| US 8,789,124 |
Lilly Diagnostics |
Diagnostic methods related to glucose transporters |
2013 |
Expired |
Trends and Focus Areas
The patent landscape indicates an increasing focus on small molecules targeting GLUT4 translocation, possibly due to better oral bioavailability than peptide counterparts. Several patent applications reference similar chemical cores, but Eli Lilly's claims specify particular substituent patterns that differentiate them.
Patent Filing and Litigation Environment
Eli Lilly's patent was filed in 2017 and granted in 2019, aligning with the broader push in the late 2010s for metabolic disorder treatment innovations. No active litigation involving this patent has been reported as of early 2023.
Geographic Coverage
While this patent covers U.S. rights, similar filings exist in Europe (via the European Patent Office) and in Asia, particularly China and Japan, under filing families to secure global rights.
Implications for R&D and Commercialization
- The broad chemical scope provides opportunities for patent-owning companies to develop targeted GLUT4 modulators.
- The patent's claims support development of oral small molecules, aligning with market trends favoring non-injectable therapies.
- Competitors must navigate potential threats from prior art and patent filings. Opportunities exist for designing around the claims by modifying substituents outside patent scope.
Key Takeaways
- U.S. Patent 10,414,748 claims a class of GLUT4 modulators with specific chemical features for treating metabolic diseases.
- The claims are broad but specific enough to defend against similar compounds, focusing on chemical structure variations that influence activity.
- The patent landscape shows intense R&D on small molecule GLUT4 regulators, with Eli Lilly's patent positioned as a significant piece in this landscape.
- The scope suggests potential for drug development, provided competitors design compounds outside the scope of the claims.
- The patent's expiration is expected around 2039, assuming maintenance fees are paid, providing a long-term strategic window.
FAQs
1. What is the primary therapeutic application of the compounds claimed in U.S. Patent 10,414,748?
Treatment of type 2 diabetes mellitus, insulin resistance, and related metabolic disorders through modulation of GLUT4 activity.
2. How broad are the claims in this patent?
Claims cover a class of chemical compounds with variations in specific substituents, allowing some flexibility while maintaining focus on GLUT4 modulation.
3. Are there similar patents in this area?
Yes, competitors like Novo Nordisk and Sanofi have filed related patents covering different GLUT4 modulators, focusing on peptides, combination therapies, and small molecules.
4. What challenges could competitors face when designing around this patent?
Designing compounds with different core structures or substituents that do not fall within the specific chemical claims but still effectively modulate GLUT4.
5. When will this patent expire, and what does this imply for market exclusivity?
Expected expiry around 2039, assuming maintenance fees are paid. This grants Eli Lilly long-term exclusivity for these compounds in the U.S.
References
[1] U.S. Patent 10,414,748. "Methods of Treatment Using Glucose Transporter 4 (GLUT4) Modulators," Eli Lilly and Company, 2019.
